4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
InnoCare Pharma Limited (9969) operates in the Biotechnology industry and is headquartered in Beijing, China. Its market capitalization is roughly CNY 25 billion. In the fiscal year ended 2025-12-31, 9969 reported CNY 2.4B in revenue and CNY 642M in net income.
InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases in China.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 2.4B | CNY 1.0B | CNY 738M | CNY 625M | — |
| Gross Profit | CNY 2.2B | CNY 871M | CNY 610M | CNY 482M | — |
| Operating Income (EBIT) | CNY 496M | (CNY 526M) | (CNY 652M) | (CNY 731M) | — |
| Net Income | CNY 642M | (CNY 441M) | (CNY 631M) | (CNY 887M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 10.8B | CNY 9.4B | CNY 9.9B | CNY 10.3B | — |
| Total Liabilities | CNY 3.1B | CNY 2.7B | CNY 2.7B | CNY 2.7B | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 9969 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms